Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2008
06/19/2008WO2008027991A3 USE OF DPA(n-6) OILS IN INFANT FORMULA
06/19/2008WO2008027584A3 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
06/19/2008WO2008025857A3 New method for the treatment of inflammatory diseases
06/19/2008WO2008024305A3 Bis (thiohydrazide amides) for treating melanoma
06/19/2008WO2008023390A3 Modified release pharmaceutical composition of bupropion hydrochloride
06/19/2008WO2008016708A3 Methods for treatment of radiation enteritis
06/19/2008WO2008016643A3 Certain chemical entities, compositions, and methods
06/19/2008WO2008009894A3 Use of imino sugars in immunotherapy
06/19/2008WO2008008507A3 Methods of treatment of diabetes
06/19/2008WO2008002582A8 Ultraviolet absorbing ophthalmic compositions
06/19/2008WO2007147882A3 Aqueous suspensions of tmc278
06/19/2008WO2007147371B1 Pharmaceutical composition for oral administration
06/19/2008WO2007146136A3 Ophthalmic compositions for treating ocular hypertension
06/19/2008WO2007144889A3 Treatment of neurofibromatosis
06/19/2008WO2007137732A3 Autodestructive transdermal therapeutic system
06/19/2008WO2007137294A3 Dexamethasone-eluting endoprosthesis to promote human coronary artery endothelial cell migration
06/19/2008WO2007130523A3 Compositions and methods for detecting and treating hiv infection
06/19/2008WO2007130383A3 Compositions and treatments using pyridazine compounds and secretases
06/19/2008WO2007127474A3 Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
06/19/2008WO2007121447A3 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
06/19/2008WO2007120726A3 Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml
06/19/2008WO2007115929A8 Thiazolyl-dihydroquinazolines
06/19/2008WO2007115181A3 Compounds exhibiting efflux inhibitor activity and compositions and uses thereof
06/19/2008WO2007111866A3 Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
06/19/2008WO2007110709A8 Formulations of tipifarnib for intravenous administration
06/19/2008WO2007109363A3 Methods and compositions for inhibiting impdh isoform 1
06/19/2008WO2007106424A3 Treating cancers with activated ras through inhibition of pkc delta
06/19/2008WO2007099302A3 Methods of maintaining oral health in animals using morpholine derivatives
06/19/2008WO2007095321A3 Mitotic progression genes and methods of modulating mitosis
06/19/2008WO2007092758A3 Crystalline forms of perindopril erbumine
06/19/2008WO2007081773A3 Treatment of fatty liver
06/19/2008WO2007058832A3 Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
06/19/2008WO2007045060A8 Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production
06/19/2008WO2007036730A9 Thiophene derivatives as ppar agonists i
06/19/2008WO2007010032A3 Intermolecular association complex of a carrier, preferably an n-alkylamino -1-desoxylactitol and of an active ingredient
06/19/2008WO2007008551A3 Use of 2-phenyl-l, 2-ethanedi0l-(di) carbamates for treating epileptogenesis and epilepsy
06/19/2008WO2006128674A8 Combinations of indacaterol derivatives and other agents for the treatment of airway diseases
06/19/2008US20080147169 Rgd peptide attached to bioabsorbable stents
06/19/2008US20080147045 Use of VEGF-C or VEGF-D in Reconstructive Surgery
06/19/2008US20080146987 Treatment of a skin condition using a piperine-based composition in conjunction with irradiation
06/19/2008US20080146836 New Aminopropylphosphinic acids
06/19/2008US20080146821 Internal 1,15-Lactones Of Fluprostenol And Related Prostaglandin F2a Analogs And Their Use In The Treatment Of Glaucoma And Intraocular Hypertension
06/19/2008US20080146818 Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes
06/19/2008US20080146808 Antiapoptosis; cancers; inhibiting the caspases;
06/19/2008US20080146807 Indazole-carboxamide compounds as 5-HT4 receptor agonists
06/19/2008US20080146803 Antibiotics containing borinic acid complexes and methods of use
06/19/2008US20080146797 Process for synthesizing heterocyclic compounds
06/19/2008US20080146793 Lipid free bacterial capsular polysaccharide for use as antithrombic and antimetastatic agents
06/19/2008US20080146785 Antibody against tumor specific antigen as target
06/19/2008US20080146676 Formed by combining solution of tannic acid with rasagiline base to form mixture, removing part of liquid, adding polar, water soluble solvent to form second mixture, removing liquid at ambient temperature from second mixture; selective inhibitor of B-form of enzyme monoamine oxidase; Parkinson's disease
06/19/2008US20080146675 Analyzing stability of atomoxetine hydrochloride by determining pH of sample of atomoxetine hydrochloride in aqueous solution; stable atomoxetine hydrochloride contains reduced amount of free hydrogen chloride, such that an aqueous solution has a pH of 4-7; shelf life, purity; attention-deficit disorder
06/19/2008US20080146674 Composition for topical application comprising an antiseptic dye present in range of 0.005 to 0.05 weight percent, the dye being gentian violet, carbol fuschin dye, Castellani's paint and/or mixtures thereof; atopic dermatitis, skin irritation caused by S. aureus, rashes, psoriasis, eczema, stings, cuts
06/19/2008US20080146673 Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same
06/19/2008US20080146672 Eutectic combination of anesthetic agents, sugar alcohol, and menthol for the purpose of numbing oral or dermal tissue; lidocaine, prilocaine, tetracaine, mannitol, sugar alcohol, menthol; for topical administration for dental, emergency and general medical use; pain free injections
06/19/2008US20080146671 Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amide renin inhibitor in absorption enhancing carrier comprising lipophilic component, high HLB surfactant, hydrophilic component, which on mixing forms stable microemulsion concentrate; bioavailability; side effect reduction; cardiovascular disorders
06/19/2008US20080146670 Guanylhydrazone salts, compositions, processes of making, and methods of using
06/19/2008US20080146669 Treating cystic fibrosis by administering a therapeutically effective amount of a compound capable of stimulating the activity of a cystic fibrosis transmembrane conductance regulator such as an arylaminobenzoate or a benzenesulfonamide derivative or curcumin
06/19/2008US20080146668 Method for stimulating weight loss and/or for lowering triglycerides in patients
06/19/2008US20080146667 An amount of at least one photolabile compound or a compound converted into a photolabile compound when present in skin is applied to skin; photolabile compound generates a biologically active agent when it penetrates skin and skin exposed to sunlight; skin rejuvenation, acne treatment
06/19/2008US20080146666 An amount of at least one photolabile compound or a compound converted into a photolabile compound when present in skin is applied to skin; photolabile compound generates a biologically active agent when it penetrates skin and skin exposed to sunlight; skin rejuvenation, acne treatment
06/19/2008US20080146665 Synergistically Heat Stable Oil Media Having Eicosa Pentanoic Acid (Epa) and Docosa Hexaenoic Acid (Dha)
06/19/2008US20080146664 Method for treating diseases caused by accumulation of body fat
06/19/2008US20080146663 Derivatives of 11-nonyloxy-undec-8(Z)-eonic acid, e.g., (Z)-1,3-dihydroxypropan-2-yl 11-(nonyloxy)undec-8-enoate; compounds mimic epoxide metabolites; for use in treatment of renal or cardiovascular disease; hypotensive agents
06/19/2008US20080146662 Methods and compositions for treatment of cancer pain
06/19/2008US20080146661 Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators
06/19/2008US20080146660 Androgen receptor antagonists; certain cancers such as colon, skin and prostate cancer, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired
06/19/2008US20080146659 Administering Taxiresinol, (7'R)-7'-Hydroxylariciresinol, Secoisolariciresinol and Isotaxiresinol, which are lignans contained in Hongdoushan contained in Hongdoushan, as the active ingredients for reducing the blood glucose level
06/19/2008US20080146658 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)-4H-chromen-4-one; for modulating functions of estrogen receptor alpha 36, preventing or treating diseases related to estrogen receptor alpha 36, such as asthma, for inducing cell death or inhibiting cell proliferation
06/19/2008US20080146657 Plant-Origin Alpha3-Adrenoceptor Agonist and Use of the Same
06/19/2008US20080146656 May be useful for treatment of hirsutism, excess sebum production, benign breast disease, benign ovarian disease, polycystic ovarian disease, female infertility; steroid sulphatase, aromatase inhibitors or modulators of apoptosis, cell cycling, cell growth; sulphamate group-containing coumarin compounds
06/19/2008US20080146655 Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases
06/19/2008US20080146654 For therapy of disease of impaired gastric motility
06/19/2008US20080146653 Synergistic anti-cancer compositions
06/19/2008US20080146652 Anhydrous formulations formed of diblock copolymer having hydrophilic block and hydrophobic block, an additive selected from a polymer and an organic solvent, the solvent being water-miscible and biocompatible, and a drug; provides for formation of micelles having enhanced ability to incorporate drugs
06/19/2008US20080146651 Injectable Composition for the Treatment of Cancers
06/19/2008US20080146650 Administering alpha -lipoic acid (LA) or dehydrolipoic acid for treating LPS-induced endotoxemia
06/19/2008US20080146649 Substituted pyrrolidine and related compounds
06/19/2008US20080146648 Less toxicity; side effects redution; administering substituted p-chlorobenzene and a pyrrolethoxybenzene
06/19/2008US20080146647 Acetylene derivatives having mglur 5 antagonistic activity
06/19/2008US20080146646 For therapy of pain, inflammation, urological disorders, gynecological disorders, gastrointestinal disorders, respiratory disorders, psoriasis, pruritus, dermal, ocular or mucous irritation, herpes or zona, diabetes, depression
06/19/2008US20080146645 Reacting compounds such as 7-Fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one with compounds such as 1R,3R)-3-(3-fluorophenyl)-2-(hydroxymethyl)oxirane in the presence of Lewis acid catalyst,a solvent and a strong non-nucleophilic base
06/19/2008US20080146644 Tricyclic Cytoprotective Compounds
06/19/2008US20080146643 Combination
06/19/2008US20080146642 Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease
06/19/2008US20080146640 Water-Soluble Prodrugs of Chloramphenicol, Thiamphenicol, and Analogs Thereof
06/19/2008US20080146639 Reducing the incidence of fibrosis by the co-administration of effective amounts of telmisartan and ramipril; strokes; cardiovascular disorders; organoprotective, tissue-protective, and vasculoprotective effects of combined treatment
06/19/2008US20080146638 primary small cell lung cancer with veliparib and temozolomide; poly/adp-ribose/polymerase (PARP)
06/19/2008US20080146637 Benzimidazole trpv1 inhibitors
06/19/2008US20080146636 For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol
06/19/2008US20080146635 Selective to alpha2B and/or alpha2C adrenergic receptors, minimal cardivascular and/or sedatory activity; treating pain, visceral pain, neuropathic pain, corneal pain, glaucoma, elevated intraocular pressure, ischemic neuropathies, neurodegenerative diseases, diarrhea, nasal congestion
06/19/2008US20080146634 2-imidazoles
06/19/2008US20080146633 Compositions for skin lightening and toning down pigment disorders, comprising creatinine and/or creatinine derivatives as active substances
06/19/2008US20080146632 Fc Receptor Modulating Compounds and Compositions
06/19/2008US20080146631 Peroxisome proliferator activated receptor modulators; diabetes mellitus; side effects reduction; 2-Methyl-2-{4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy}propionic acid; Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis
06/19/2008US20080146630 Estrogen receptor modulators; neurodegenerative disorders; cognitive enhancement
06/19/2008US20080146629 Novel thiazolidin-4-one derivatives
06/19/2008US20080146628 Lowering prolactin serum level; attention deficit hyperactivity disorder (ADHD)
06/19/2008US20080146627 Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain.
06/19/2008US20080146626 Use of epothilones in the treatment of osteoporosis and related diseases
06/19/2008US20080146625 Oxime glucokinase activators